Published in J Thromb Haemost on October 01, 2004
Assessing risk of venous thromboembolism in the patient with cancer. J Clin Oncol (2009) 2.22
Epidemiology and pathophysiology of cancer-associated thrombosis. Br J Cancer (2010) 1.93
Risk of venous thromboembolism in patients with cancer: a systematic review and meta-analysis. PLoS Med (2012) 1.60
Paraneoplastic syndromes associated with lung cancer. World J Clin Oncol (2014) 1.25
Rationale and design of PROSPECT-CONKO 004: a prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy). BMC Cancer (2008) 1.02
Cancer-related coagulopathy (Trousseau's syndrome): review of the literature and experience of a single center of internal medicine. Clin Exp Med (2013) 1.01
Clues to occult cancer in patients with ischemic stroke. PLoS One (2012) 0.93
Do circulating tumor cells play a role in coagulation and thrombosis? Front Oncol (2012) 0.92
Holothurian glycosaminoglycan inhibits metastasis and thrombosis via targeting of nuclear factor-κB/tissue factor/Factor Xa pathway in melanoma B16F10 cells. PLoS One (2013) 0.89
Examination of thromboxane synthase as a prognostic factor and therapeutic target in non-small cell lung cancer. Mol Cancer (2011) 0.87
Doxorubicin-induced vascular toxicity--targeting potential pathways may reduce procoagulant activity. PLoS One (2013) 0.84
Pulmonary embolism, myocardial infarction, and ischemic stroke in lung cancer patients: results from a longitudinal study. Lung (2013) 0.82
Thrombin regulates the metastatic potential of human rhabdomyosarcoma cells: distinct role of PAR1 and PAR3 signaling. Mol Cancer Res (2010) 0.82
Real-Time Label-Free Embolus Detection Using In Vivo Photoacoustic Flow Cytometry. PLoS One (2016) 0.82
Acute Fatal Liver Toxicity under Erlotinib. Case Rep Oncol (2010) 0.81
The incidence and predictors of thromboembolic events in patients with lung cancer. ScientificWorldJournal (2014) 0.80
Incidence of and risk factors for venous thromboembolism during surgical treatment for esophageal cancer: a single-institution study. Surg Today (2015) 0.79
Clinical characteristics of pulmonary embolism with underlying malignancy. Korean J Intern Med (2010) 0.76
Venous thromboembolism and lung cancer: a review. Multidiscip Respir Med (2015) 0.76
Thromboembolic events following brachytherapy: case reports. J Contemp Brachytherapy (2015) 0.75
Limb necrosis in a lung cancer case presenting with widespread thrombosis. Case Rep Vasc Med (2012) 0.75
Risk factors and prognosis of pulmonary embolism in patients with lung cancer. Medicine (Baltimore) (2017) 0.75
Cerebral infarction in advanced non-small cell lung cancer: a case control study. BMC Cancer (2016) 0.75
Venous Thromboembolism in Cancer: An Update of Treatment and Prevention in the Era of Newer Anticoagulants. Front Cardiovasc Med (2016) 0.75
Extensive Bilateral Lemierre Syndrome due to Methicillin-Resistant Staphylococcus epidermidis in a Patient with Lung Adenocarcinoma. Tuberc Respir Dis (Seoul) (2015) 0.75
LUNG CANCER AND PULMONARY THROMBOEMBOLISM. Mater Sociomed (2015) 0.75
Massive hypercoagulable state despite full-dose anticoagulant treatment in a patient with occult malignancy: considerations concerning chemotherapy without definitive diagnosis. BMJ Case Rep (2010) 0.75
Risk of venous thromboembolism in people with lung cancer: a cohort study using linked UK healthcare data. Br J Cancer (2016) 0.75
Hypertension associated with venous thromboembolism in patients with newly diagnosed lung cancer. Sci Rep (2016) 0.75
Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature (1994) 9.06
The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA (1995) 7.31
Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet (1994) 5.58
Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet (1994) 5.45
Oral contraceptives and the risk of myocardial infarction. N Engl J Med (2001) 5.18
Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med (1995) 5.16
Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet (1995) 5.10
End of the line for "third-generation-pill" controversy? Lancet (1997) 4.63
The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study. BMJ (2009) 4.18
Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysis. Lancet (1992) 4.15
Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med (1996) 4.11
Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost (2007) 4.09
Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet (1995) 4.01
Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses. Circulation (1994) 3.65
Incidence of venous thrombosis in a large cohort of 66,329 cancer patients: results of a record linkage study. J Thromb Haemost (2006) 3.49
Increased fetal loss in women with heritable thrombophilia. Lancet (1996) 3.34
Is publication bias a medical problem? Lancet (1993) 3.04
Microparticle-associated tissue factor activity: a link between cancer and thrombosis? J Thromb Haemost (2006) 3.03
[Guideline 'Renal cell carcinoma']. Ned Tijdschr Geneeskd (2008) 2.89
Assessment and control for confounding by indication in observational studies. J Am Geriatr Soc (1999) 2.71
Bleeding complications in oral anticoagulant therapy. An analysis of risk factors. Arch Intern Med (1993) 2.70
Oral contraceptives and the risk of venous thrombosis. N Engl J Med (2001) 2.57
High levels of coagulation factor XI as a risk factor for venous thrombosis. N Engl J Med (2000) 2.39
Antipsychotic medication and venous thrombosis. Br J Psychiatry (2001) 2.37
Atomic force microscopy: a novel approach to the detection of nanosized blood microparticles. J Thromb Haemost (2009) 2.33
Activation of coagulation system during air travel: a crossover study. Lancet (2006) 2.32
Cigarette smoking and the risk of venous thromboembolism: the Tromsø Study. J Thromb Haemost (2012) 2.30
Interaction of coagulation defects and cardiovascular risk factors: increased risk of myocardial infarction associated with factor V Leiden or prothrombin 20210A. Circulation (1998) 2.26
Surrogate end points, health outcomes, and the drug-approval process for the treatment of risk factors for cardiovascular disease. JAMA (1999) 2.21
Mortality due to pulmonary embolism, myocardial infarction, and stroke among incident dialysis patients. J Thromb Haemost (2012) 2.17
Risk of a first venous thrombotic event in carriers of a familial thrombophilic defect. The European Prospective Cohort on Thrombophilia (EPCOT). J Thromb Haemost (2005) 2.13
Patients with type 3 severe von Willebrand disease are not protected against atherosclerosis: results from a multicenter study in 47 patients. Circulation (2004) 2.12
Factor V Leiden: should we screen oral contraceptive users and pregnant women? BMJ (1996) 2.11
Protein C deficiency in a controlled series of unselected outpatients: an infrequent but clear risk factor for venous thrombosis (Leiden Thrombophilia Study) Blood (1995) 2.09
Use of preventive measures for air travel-related venous thrombosis in professionals who attend medical conferences. J Thromb Haemost (2006) 2.06
Current perspective of venous thrombosis in the upper extremity. J Thromb Haemost (2008) 2.06
Increased levels of factor VIII and fibrinogen in patients with venous thrombosis are not caused by acute phase reactions. Thromb Haemost (1999) 2.04
The family history and inherited thrombophilia. Br J Haematol (1994) 2.03
Mortality and causes of death in patients with hemophilia, 1992-2001: a prospective cohort study. J Thromb Haemost (2006) 2.01
Seasonal variation of venous thrombosis: a consecutive case series within studies from Leiden, Milan and Tromsø. J Thromb Haemost (2012) 2.01
Inherited thrombophilia: Part 1. Thromb Haemost (1996) 2.00
Is hyperhomocysteinaemia a risk factor for recurrent venous thrombosis? Lancet (1995) 2.00
Mortality from venous thromboembolism and myocardial infarction in young women in the Netherlands. Lancet (1996) 1.99
Increased risk of venous thrombosis in carriers of hereditary protein C deficiency defect. Lancet (1993) 1.96
Risk of venous thrombosis with use of current low-dose oral contraceptives is not explained by diagnostic suspicion and referral bias. Arch Intern Med (1999) 1.95
Extrahepatic portal vein thrombosis: aetiology and determinants of survival. Gut (2001) 1.86
Second-generation recombinant factor VIII and inhibitor risk: interpretation of RODIN study findings and implications for patients with haemophilia A. Haemophilia (2013) 1.84
von Willebrand factor and its propeptide: the influence of secretion and clearance on protein levels and the risk of venous thrombosis. J Thromb Haemost (2006) 1.84
The natural history of chronic hepatitis C in haemophiliacs. Br J Haematol (1996) 1.76
Decreased mortality of ischaemic heart disease among carriers of haemophilia. Lancet (2003) 1.76
Old and new risk factors for upper extremity deep venous thrombosis. J Thromb Haemost (2005) 1.73
Course of the international Normalized Ratio in response to oral vitamin K1 in patients overanticoagulated with phenprocoumon. Br J Haematol (1999) 1.69
The Leiden Thrombophilia Study (LETS). Thromb Haemost (1997) 1.65
Risk of stroke in young women and two prothrombotic mutations: factor V Leiden and prothrombin gene variant (G20210A) Stroke (1998) 1.63
Increased end-stage diabetic nephropathy in Indo-Asian immigrants living in the Netherlands. Diabetologia (2002) 1.63
Usefulness of patient interview in bleeding disorders. Arch Intern Med (1995) 1.62
High levels of factor IX increase the risk of venous thrombosis. Blood (2000) 1.61
N-ras mutations in human cutaneous melanoma from sun-exposed body sites. Mol Cell Biol (1989) 1.61
Prevalence of the metabolic syndrome and cardiovascular disease risk in chemotherapy-treated testicular germ cell tumour survivors. Br J Cancer (2013) 1.60
Third-generation oral contraceptive and deep venous thrombosis: from epidemiologic controversy to new insight in coagulation. Am J Obstet Gynecol (1997) 1.59
Risk factor profiles in patients with different clinical manifestations of venous thromboembolism: a focus on the factor V Leiden mutation. Thromb Haemost (1996) 1.58
Pregnancy, the postpartum period and prothrombotic defects: risk of venous thrombosis in the MEGA study. J Thromb Haemost (2008) 1.57
Coagulation factor activity and clinical bleeding severity in rare bleeding disorders: results from the European Network of Rare Bleeding Disorders. J Thromb Haemost (2012) 1.56
The RATIO study: oral contraceptives and the risk of peripheral arterial disease in young women. J Thromb Haemost (2003) 1.55
Different effects of oral contraceptives containing different progestogens on protein S and tissue factor pathway inhibitor. J Thromb Haemost (2007) 1.55
Proof of principle of potential clinical utility of multiple SNP analysis for prediction of recurrent venous thrombosis. J Thromb Haemost (2008) 1.53
Analysis of low frequency bleeding data: the association of joint bleeds according to baseline FVIII activity levels. Haemophilia (2010) 1.51
Thromboembolic events during chemotherapy for germ cell cancer: a cohort study and review of the literature. J Clin Oncol (2000) 1.51
Genome scan of venous thrombosis in a pedigree with protein C deficiency. J Thromb Haemost (2004) 1.49
The role of compliance as a cause of instability in oral anticoagulant therapy. Br J Haematol (1997) 1.48
Polymorphisms in coagulation factors and the risk of recurrent cardiovascular events in men after a first myocardial infarction. J Thromb Haemost (2008) 1.45
Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis. Blood (2000) 1.45
Competing interests and controversy about third generation oral contraceptives. BMJ readers should know whose words they read. BMJ (2000) 1.45
Familial thrombophilia and lifetime risk of venous thrombosis. J Thromb Haemost (2004) 1.44
A prospective study of anticardiolipin antibodies as a risk factor for venous thrombosis in a general population (the HUNT study). J Thromb Haemost (2006) 1.43
Effect of aspirin intake at bedtime versus on awakening on circadian rhythm of platelet reactivity. A randomised cross-over trial. Thromb Haemost (2014) 1.43
Assessment of therapeutic quality control in a long-term anticoagulant trial in post-myocardial infarction patients. Thromb Haemost (1994) 1.41
Emergency oral anticoagulant reversal: the relative efficacy of infusions of fresh frozen plasma and clotting factor concentrate on correction of the coagulopathy. Thromb Haemost (1997) 1.41
Factor VII and fibrinogen levels as risk factors for venous thrombosis. A case-control study of plasma levels and DNA polymorphisms--the Leiden Thrombophilia Study (LETS). Thromb Haemost (1994) 1.41
Effect of prolonged sitting on thrombin generation: not evidenced yet: rebuttal. J Thromb Haemost (2003) 1.40
A randomized and blinded comparison of three bleeding time techniques: the Ivy method, and the Simplate II method in two directions. Thromb Haemost (1992) 1.40
[The thrombosis service as a source of information for studies in patients with heart valve prostheses]. Ned Tijdschr Geneeskd (1992) 1.40
[Interferon for adjuvant therapy in melanoma; although approved, not indicated]. Ned Tijdschr Geneeskd (2000) 1.39
Activated protein C resistance: a comparison between two clotting assays and their relationship to the presence of the factor V Leiden mutation. Br J Haematol (1996) 1.39
Evidence for familial aggregation of hand, hip, and spine but not knee osteoarthritis in siblings with multiple joint involvement: the GARP study. Ann Rheum Dis (2004) 1.39
A case of thrombosis at high altitude. Thromb Haemost (2005) 1.38
[New drugs; sunitinib and sorafenib]. Ned Tijdschr Geneeskd (2007) 1.37
The plasma hemostatic proteome: thrombin generation in healthy individuals. J Thromb Haemost (2005) 1.35
Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism--pooled analysis of 8 case-control studies including 2310 cases and 3204 controls. Study Group for Pooled-Analysis in Venous Thromboembolism. Thromb Haemost (2001) 1.34
Inherited thrombophilia: Part 2. Thromb Haemost (1996) 1.34
Haplotypes of the EPCR gene, plasma sEPCR levels and the risk of deep venous thrombosis. J Thromb Haemost (2004) 1.33
Prothrombotic conditions, oral contraceptives, and the risk of ischemic stroke. J Thromb Haemost (2005) 1.29
Patient self-management of oral anticoagulant care vs. management by specialized anticoagulation clinics: positive effects on quality of life. J Thromb Haemost (2004) 1.26